{"entity":{"id":"paper-cd19-dlbcl-clin-cancer-res-2011","kind":"paper","name":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","aka":[],"tldr":"Review on CD19 in Diffuse large B-cell lymphoma, in Clinical Cancer Research (2011), one of the most cited Europe PMC records with CD19 in its title.","summary":"SAR3419 is a novel anti-CD19 humanized monoclonal antibody conjugated to a maytansine derivate through a cleavable linker for the treatment of B-cell malignancies. SAR3419 combines the strengths of a high-potency tubulin inhibitor and the exquisite B-cell selectivity of an anti-CD19 antibody. The internalization and processing of SAR3419, following its binding at the surface of CD19-positive human lymphoma cell lines and xenograft models, release active metabolites that trigger cell-cycle arrest and apoptosis, leading to cell death and tumor regression. SAR3419 has also been shown to be active in different lymphoma xenograft models, including aggressive diffuse large B-cell lymphoma, resulting in complete regressions and tumor-free survival. In these models, the activity of SAR3419 compared favorably with rituximab and lymphoma standard of care chemotherapy. Two phase I trials with 2 different schedules of SAR3419 as a single agent were conducted in refractory/relapsed B-cell non-Hodgkin lymphoma. Activity was reported in both schedules, in heavily pretreated patients of both follicular and diffuse large B-cell lymphoma subtypes, with a notable lack of significant hematological toxicity, validating SAR3419 as an effective antibody-drug conjugate and opening opportunities in the future. Numerous B-cell-specific anti-CD19 biologics are available to treat B-cell non-Hodgkin lymphoma, and early phase I results obtained with SAR3419 suggest that it is a promising candidate for further development in this disease. In addition, thanks to the broad expression of CD19, SAR3419 may provide treatment options for B-cell leukemias that are often CD20-negative.\n\nIndexed on Europe PMC as PubMed record 22003072 (DOI 10.1158/1078-0432.ccr-11-0485). Its title names CD19 and its text names Diffuse large B-cell lymphoma; PubMed types it as a review (Review). It was matched automatically to the idea \"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma\" and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Clin Cancer Res 2011","url":"https://doi.org/10.1158/1078-0432.ccr-11-0485"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/22003072/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/22003072"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2011,"doi":"10.1158/1078-0432.ccr-11-0485","pmid":"22003072","authors":"Blanc V, Bousseau A, Caron A, et al.","paperType":"review","findings":[],"whatItMeans":"One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched by CD19 in the title and Diffuse large B-cell lymphoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","A review summarises other studies; the primary reports it cites are the evidence."]},"route":"/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/","neighbours":{"journal":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/"}],"idea":[{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/"},{"id":"idea-reg-non-viral-cart-manufacturing","kind":"idea","name":"Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route","route":"/ideas/idea-reg-non-viral-cart-manufacturing/"}]}}